Azenta, Inc. (AZTA) Stock Price & Analysis

Azenta, Inc. (AZTA) closed at USD 41.27 on Thursday, October 29, 2026, up 1.58% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 40.63; the Oct 29, 2026 session ranged USD 40.46–41.7 on volume of 822,481 shares. Market capitalization is $1.81B, with a 52-week range of USD 15.93–46.41 (NMS). Source: Nexqual, retrieved October 30, 2026 at 00:13 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AZTA.md

Key facts (AZTA)

• Last four reported quarters (through Jun 30, 2026): revenue $614M, net income -$123M (-20.0% margin), free cash flow $9.9M (SEC filings).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $164K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 37.8 (range 33–44).
• Total return with dividends: 1Y +35.9% vs S&P 500 +14.8%; 5Y -64.5% vs S&P 500 +79.1%.
• Next earnings: 2026-11-10, EPS estimate USD 0.11, revenue estimate $160M. All companies reporting that day: https://nexqual.com/earnings/2026-11-10
• Dividend: USD 0 paid over the last 12 months; latest ex-dividend date 2021-12-02.
• Short interest: 19.87% of float (as of 2026-10-15), 4.4 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AZTA)

Fiscal years end Sep. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AZTA)

P/S 3.0x · P/FCF 183.0x · P/B 1.2x · FCF yield 0.55% · Earnings yield -6.80%

Insider purchases (SEC Form 4, open-market, last ~7 months) (AZTA)

1 purchase, $164K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (AZTA)

Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 37.8 (low 33, high 44).

Rating changes, last 120 days:

Total return (dividends reinvested) (AZTA)

Dividends (AZTA)

Dividend. Paid over the last 12 months: USD 0.00 in 0 payments.

Most recent ex-dividend date: Dec 2, 2021; payment date: Dec 23, 2021. To receive a dividend, shares must be owned before the ex-dividend date.

5-year average yield 1.05%.

Short interest (AZTA)

5,362,594 shares sold short, 19.87% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,382,386 shares (-0.4%). Days to cover: 4.4 (short shares ÷ average daily volume).

AZTA earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

AZTA recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AZTA company outlook (results filed Aug 4, 2026)

• “Fiscal 2026 Guidance - Continuing Operations • Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025. • Adjusted EBITDA is expected to range approximately between $20 million and $23 million.”

Analysts expect $160.2M for the current quarter, 645.1% above the midpoint of the company's guidance ($21.5M).

Quoted word-for-word from the SEC 8-K results press release.

AZTA analyst estimates and revisions

AZTA options: expected move

Options price a move of about ±12.4% (±$5.05) by Nov 20, 2026, which includes earnings on Nov 10, 2026. Over the last 8 reports the stock moved ±13.1% on average.

30-day implied volatility 69.5% vs 67.8% realized over the last 30 trading days. Put/call ratio (volume) 0.01. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 30, 2026 at 00:13 UTC)

Technical Analysis (AZTA)

Nexqual's technical model rates AZTA "BUY" based on 5 bullish and 1 bearish signals across 126 daily candles, as of October 30, 2026 at 00:13 UTC.

Analyst Ratings (AZTA)

Wall Street analysts rate AZTA "Buy" based on 6 analysts, with a mean price target of USD 37.8 (range USD 33–44), per Nexqual as of October 30, 2026 at 00:13 UTC.

Earnings (AZTA)

Recent Earnings History

Source: Nexqual, October 30, 2026 at 00:13 UTC.

Financials & Fundamentals (AZTA)

Source: Nexqual, October 30, 2026 at 00:13 UTC.

Financial Health Score (AZTA)

Nexqual rates Azenta, Inc.'s overall financial health "Mixed" across five dimensions, as of October 30, 2026 at 00:13 UTC.

Ownership (AZTA)

Source: Nexqual, October 30, 2026 at 00:13 UTC.

Leadership (AZTA)

Azenta, Inc. is led by Martin D. Madaus D.V.M., Interim President, CEO & Director, per Nexqual as of October 30, 2026 at 00:13 UTC.

Major Backers & Investors (AZTA)

Notable institutional backers of Azenta, Inc. include Politan Capital Management LP, Massachusetts Financial Services Co., Shaw D.E. & Co., Inc., according to Nexqual as of October 30, 2026 at 00:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 30, 2026 at 00:13 UTC.

From Azenta, Inc.'s Latest SEC 10-K Filing (filed 2025-12-04)

Key Strengths & Strategy (as disclosed to the SEC)

• Within our Sample Management Solutions segment, we operate as a single business unit offering end-to-end sample management products and services, including SRS and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices).
• Our expertise, global footprint, and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions.
• We have developed and continue to develop automated biological sample storage solutions for operating in ultra-low temperature environments.
• We rely on patents, trade secret laws, confidentiality agreements and procedures, copyrights, trademarks and licensing agreements to protect our technology.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes in tax rates or tax regulation could affect results of operations.
• Regulations and customer demands related to conflict minerals may adversely affect us.
• Risks Related to Cybersecurity and Data Privacy
• Our business relies on certain critical information systems and a failure or breach of such a system could harm our business and results of operations and, in the event of unauthorized access to a customer's data or our data, incur significant legal and financial exposure and liabilities.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 30, 2026 at 00:13 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt